These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 11002904)

  • 21. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
    Rösner S; Leucht S; Lehert P; Soyka M
    J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acamprosate in alcohol dependence: how does it work?
    Littleton J
    Addiction; 1995 Sep; 90(9):1179-88. PubMed ID: 7580816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-craving drugs acamprosate and naloxone do not reduce expression of morphine conditioned place preference in isolated and group-housed rats.
    Herzig V; Schmidt WJ
    Neurosci Lett; 2005 Feb; 374(2):119-23. PubMed ID: 15644276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1.
    Kenna GA; McGeary JE; Swift RM
    Am J Health Syst Pharm; 2004 Nov; 61(21):2272-9. PubMed ID: 15552634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system.
    Cowen MS; Adams C; Kraehenbuehl T; Vengeliene V; Lawrence AJ
    Addict Biol; 2005 Sep; 10(3):233-42. PubMed ID: 16109584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mosaic of addiction.
    O'Brien CP
    Am J Psychiatry; 2004 Oct; 161(10):1741-2. PubMed ID: 15465965
    [No Abstract]   [Full Text] [Related]  

  • 27. The anti-craving drug acamprosate inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats.
    Kratzer U; Schmidt WJ
    Neurosci Lett; 1998 Aug; 252(1):53-6. PubMed ID: 9756357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
    Morley KC; Teesson M; Reid SC; Sannibale C; Thomson C; Phung N; Weltman M; Bell JR; Richardson K; Haber PS
    Addiction; 2006 Oct; 101(10):1451-62. PubMed ID: 16968347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of acamprosate on ethanol-seeking and self-administration in the rat.
    Czachowski CL; Legg BH; Samson HH
    Alcohol Clin Exp Res; 2001 Mar; 25(3):344-50. PubMed ID: 11290844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternatives to naltrexone in animal models.
    Overstreet DH
    Alcohol Clin Exp Res; 1996 Nov; 20(8 Suppl):231A-235A. PubMed ID: 8947271
    [No Abstract]   [Full Text] [Related]  

  • 31. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats.
    Heyser CJ; Schulteis G; Durbin P; Koob GF
    Neuropsychopharmacology; 1998 Feb; 18(2):125-33. PubMed ID: 9430136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of alcohol use disorders pharmacotherapies in a new preclinical model of binge drinking.
    González-Marín MC; Lebourgeois S; Jeanblanc J; Diouf M; Naassila M
    Neuropharmacology; 2018 Sep; 140():14-24. PubMed ID: 30031019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cue-induced behavioural activation: a novel model of alcohol craving?
    Pickering C; Liljequist S
    Psychopharmacology (Berl); 2003 Jul; 168(3):307-13. PubMed ID: 12684740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats.
    Simms JA; Steensland P; Medina B; Abernathy KE; Chandler LJ; Wise R; Bartlett SE
    Alcohol Clin Exp Res; 2008 Oct; 32(10):1816-23. PubMed ID: 18671810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
    Kiefer F; Jahn H; Otte C; Demiralay C; Wolf K; Wiedemann K
    J Psychiatr Res; 2005 Sep; 39(5):545-51. PubMed ID: 15992564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can craving be modeled in animals? The relapse prevention perspective.
    Littleton J
    Addiction; 2000 Aug; 95 Suppl 2():S83-90. PubMed ID: 11002905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat.
    Bachteler D; Economidou D; Danysz W; Ciccocioppo R; Spanagel R
    Neuropsychopharmacology; 2005 Jun; 30(6):1104-10. PubMed ID: 15668725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acamprosate: recent findings and future research directions.
    Mann K; Kiefer F; Spanagel R; Littleton J
    Alcohol Clin Exp Res; 2008 Jul; 32(7):1105-10. PubMed ID: 18540918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain.
    Gual A; Lehert P
    Alcohol Alcohol; 2001; 36(5):413-8. PubMed ID: 11524307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Acamprosate and naltrexone: similar efficacy for relapse].
    Saitz R
    Rev Med Suisse; 2014 Dec; 10(455):2437. PubMed ID: 25752019
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.